- Measures of response: RECIST, WHO, and new alternativesC Carl Jaffe
Diagnostic Imaging Branch, Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
J Clin Oncol 24:3245-51. 2006....
- Response assessment in clinical trials: implications for sarcoma clinical trial designC Carl Jaffe
National Cancer Institute, 6116 Executive Boulevard, Bethesda, Maryland 20892, USA
Oncologist 13:14-8. 2008..Reviewing existing and new approaches in the design of clinical trials will help to optimize the clinical development and evaluation of new therapies for sarcomas...
- Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?Lori E Dodd
Division of Cancer Treatment and Diagnosis, Branches of Biometric Research, Investigational Drug, Cancer Investigations, and Diagnostic Imaging, National Cancer Institute, Rockville, MD 20892, USA
J Clin Oncol 26:3791-6. 2008..When such designs are not practical, BICR is not recommended as a general strategy for reducing bias. However, BICR may be useful as an auditing tool to assess the reliability of marginally positive results...